Rhinosinusitis

Neurology·MeSH: Rhinosinusitis

Prevalence

12000.0 / 100K

Incidence

1000.0 / 100K/yr

16 drugs in development·10 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
xhance	Paratek Pharmaceuticals, Inc. (PRTK)

Phase 3(5)

Drug	Company
itepekimab	Sanofi (SNY)
Itepekimab	Sanofi (SNY)
lunsekimig	Sanofi (SNY)
LY3650150	ELI LILLY & Co (LLY)
Mometasone furoate nasal spray	Sanofi (SNY)

Phase 2(7)

Drug	Company
Antiretroviral Therapy	ELI LILLY & Co (LLY)
Itepekimab	REGENERON PHARMACEUTICALS, INC. (REGN)
lunsekimig	Sanofi (SNY)
Mometasone furoate nasal spray	INSMED Inc (INSM)
Oral versus topical antibioitics	UNITED THERAPEUTICS Corp (UTHR)
verekitug	Upstream Bio, Inc. (UPB)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

BLA Filed(1)

Drug	Company
xhance	OptiNose, Inc. (OPTN)

Phase 4(2)

Drug	Company
CM326 injection	Crinetics Pharmaceuticals, Inc. (CRNX)
omalizumab	Sanofi (SNY)

BioSniper tracks 16 drugs in development for Rhinosinusitis across 10 companies.

There are 1 clinical trial targeting Rhinosinusitis tracked by BioSniper.

The estimated prevalence of Rhinosinusitis is approximately 12000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.